Coronavirus Disease 2019 (COVID-19) has had a devastating impact on the ability of highly trained healthcare providers to render sufficient care, due to both the significant demand on resources and the unique nature of this disease that make it resistant to traditional therapies. This review sought to determine the potential role of phosphodiesterase-5 inhibitors (PDE-5) in the management of COVID-19 by extrapolating relevant data and clinical studies from other related disease states, including acute respiratory distress syndrome, acute lung injury, and high altitude pulmonary edema. Following a literature search, 4 reports were analyzed and included in this review. While the heterogenicity of data and the small number of trials included limit the interpretation and applicability, it was consistently demonstrated that PDE-5 inhibitors lowered pulmonary arterial pressures. The overall benefit of these agents is seemingly dependent upon the etiology of the respiratory failure, which warrants expanded clinical investigation for COVID-19.
BoyleAJMacSweeneyRMcauleyDF. Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med. 2013;11(1):166.
2.
RubenfeldGDCaldwellEPeabodyE, et al.Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–1693.
3.
HerridgeMSCheungAMTanseyCM, et al.One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348(8):683–693.
4.
SolaimanzadehI.Acetazolamide, nifedipine and phosphodiesterase inhibitors: rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (COVID-19). Cureus. 2020;12(3): e7343.
5.
WangDHuBHuC, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
6.
SteinbergKPHudsonLDGoodmanRB, et al.Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671–1684.
7.
PapazianLForelJMGacouinA, et al.Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–1116.
8.
MatthayMABrowerRGCarsonS, et al.Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011;184(5):561–568.
9.
SmithFGPerkinsGDGatesS, et al.Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet. 2012;379(9812):229–235.
10.
PerkinsGDMcAuleyDFThickettDRGaoF. The β-Agonist Lung Injury Trial (BALTI) a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med. 2006;173(2):281–287.
11.
SearcyRJMoralesJRFerreiraJAJohnsonDW. The role of inhaled prostacyclin in treating acute respiratory distress syndrome. Ther Adv Respir Dis. 2015;9(6):302–312.
12.
GoffiAFergusonN. High-frequency oscillatory ventilation for early acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20(1):77–85.
13.
BeitlerJShaefiSMontesiS, et al.Prone positioning reduces mortality from acute respiratory distress syndrome in the low tidal volume era: a meta analysis. Intensive Care Med. 2014;40(3):332–341.
14.
DunkleyKLouzonPLeeJVuS. Efficacy, safety, and medication errors associated with the use of inhaled epoprostenol for adults with acute respiratory distress syndrome: a pilot study. Ann Pharmacother. 2013;47(6):332–341.
15.
TorbicHSzumitaPMAngerKENuccioPLaGambinaSWeinhouseG. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care. 2013;28(5):844–848.
16.
GalieNGhofraniHATorbickiA, et al.Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–2157.
17.
MuzaffarSShuklaNSrivastavaAAngeliniGDJeremyJY. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol. 2005;146(1):109–117.
18.
GuptaRKHimashreeGSinghK, et al.Elevated pulmonary artery pressure and brain natriuretic peptide in high altitude pulmonary edema susceptible non-mountaineers. Sci Rep. 2016;6:21357.
19.
CornetADHofstraJJSwartELGirbesARJuffermansNP. Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Med2010;36(5):758–764.
20.
SjövallFMorotaSFrostnerEÅHanssonMJElmérE. Cytokine and nitric oxide levels in patients with sepsis--temporal evolvement and relation to platelet mitochondrial respiratory function. Plos One. 2014;9(5): e97673.
21.
SwensonERMaggioriniMMongovinS, et al.Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. Jama. 2002;287(17):2228–2235.
22.
MaggioriniMBrunner-La RoccaHPPethS, et al.Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. 2006;145(7):497–506.
23.
FischlerMMaggioriniMDorschnerL, et al.Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema. Am J Respir Crit Care Med. 2009;180(4):346–352.
24.
DuplainHSartoriCLeporiM, et al.Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med. 2000;162(1):221–224.
25.
TangKShaoXLiuF, et al.Correlation between nitric oxide content in exhaled breath condensate and the severity of acute respiratory distress syndrome. Int J Clin Exp Pathol2017;10(7):7350–7355.
26.
GiacominiMBorottoEBosottiL, et al.Vardenafil and weaning from inhaled nitric oxide: effect on pulmonary hypertension in ARDS. Anaesth Intensive Care. 2007; 35(1): 91–93.
